Compare NUTX & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUTX | VOR |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | 944 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 655.4M | 755.7M |
| IPO Year | 2009 | 2021 |
| Metric | NUTX | VOR |
|---|---|---|
| Price | $101.67 | $14.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $252.50 | $45.33 |
| AVG Volume (30 Days) | 139.8K | ★ 1.3M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.93 | N/A |
| EPS | ★ 10.48 | N/A |
| Revenue | ★ $875,257,000.00 | N/A |
| Revenue This Year | $8.28 | N/A |
| Revenue Next Year | $1.96 | N/A |
| P/E Ratio | $10.36 | ★ N/A |
| Revenue Growth | ★ 82.36 | N/A |
| 52 Week Low | $77.21 | $0.13 |
| 52 Week High | $193.07 | $49.95 |
| Indicator | NUTX | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 49.36 | 48.75 |
| Support Level | $94.38 | $11.38 |
| Resistance Level | $108.47 | $16.88 |
| Average True Range (ATR) | 6.27 | 1.57 |
| MACD | 1.50 | -0.08 |
| Stochastic Oscillator | 54.68 | 21.95 |
Nutex Health Inc is a physician-led, healthcare services and operations company with various hospital facilities in the U.S. states (hospital division), and a primary care-centric, risk-bearing population health management division. The company has three segments: the hospital division, the PHM division, and the real estate division. The hospital division implements and operates health care models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management (PHM) division owns and operates provider networks such as independent physician associations (IPAs). The Real Estate Entities own the land and hospital buildings which are leased to its hospital entities. The majority of the revenue is derived from the Hospital division.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.